-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Benzinga·05/28/2025 12:25:28
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.